Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Number of medications is associated with outcomes in the elderly patient with metabolic syndrome.

Patel AY, Shah P, Flaherty JH.

J Geriatr Cardiol. 2012 Sep;9(3):213-9. doi: 10.3724/SP.J.1263.2011.12011.

2.
3.
4.

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.

Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB.

Clin Ther. 2003 Jun;25(6):1670-86.

PMID:
12860491
6.
7.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
8.
9.

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS.

Curr Med Res Opin. 2005 Dec;21(12):1997-2006.

PMID:
16368051
10.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
12.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly..

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. French.

PMID:
19748369
13.

Leptin and metabolic syndrome in obese and non-obese children.

Moreno LA, Pineda I, Rodríguez G, Fleta J, Giner A, Juste MG, Sarría A, Bueno M.

Horm Metab Res. 2002 Jul;34(7):394-9.

PMID:
12189588
14.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
15.

Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus.

Boney CM, Verma A, Tucker R, Vohr BR.

Pediatrics. 2005 Mar;115(3):e290-6.

PMID:
15741354
16.
17.

The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.

Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA, Dimitriou KC, Pappas SI, Karamanos BG, Karamitsos DT.

Curr Med Res Opin. 2004 Sep;20(9):1393-401.

PMID:
15383188
18.

Prevalence of metabolic syndrome among Filipino adults aged 20 years and over.

Tanchoco CC, Cruz AJ, Duante CA, Litonjua AD.

Asia Pac J Clin Nutr. 2003;12(3):271-6.

19.
Items per page

Supplemental Content

Support Center